Clinical Trials

Enrolling Trials

51-60  of  152
APEC1621C, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Manalang, Michelle
Mutations
Adult, Child
This phase II trial studies how well tazemetostat works in treating patients with solid tumors, non-hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment and have EZH2, SMARCB1, or SMARCA4 gene mutations. Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
APEC1621D, NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients With Solid Tumors
Manalang, Michelle
Mutations
Child
This phase II trial studies how well PI3K/mTOR inhibitor LY3023414 works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body and have come back or do not respond to treatment. PI3K/mTOR inhibitor LY3023414 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
APEC1621F, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
Manalang, Michelle
Mutations
Child
This phase II trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back or do not respond to treatment and have spread to other places in the body. Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
APEC1621SC, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Manalang, Michelle
Mutations
Child, Adult
This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Abdelhadi, Kareem H
Rare Tumors - Pancreas
Adult
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Wilson, Anna E
(715) 858-6860
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
AREN03B2, Renal Tumors Classification, Biology, and Banking Study
Manalang, Michelle
Biology
Child
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Welter, Stacy L
(715) 221-6492
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
ARST1431, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Manalang, Michelle
Rhabdomyosarcoma/Soft Tissue Sarcoma
Soft Tissue, Bone - Soft Tissue Sarcoma
Child, Adult
This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide) alternated with vincristine sulfate and irinotecan hydrochloride works compared to combination chemotherapy alternated with vincristine sulfate, irinotecan hydrochloride and temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Irinotecan hydrochloride and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy alternated with vincristine sulfate and irinotecan hydrochloride or vincristine sulfate, irinotecan hydrochloride, and temsirolimus is more effective in treating patients with intermediate-risk rhabdomyosarcoma.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
BAROSTIM THERAPYâ„¢ in Heart Failure With Reduced Ejection Fraction: A Post-Market Registry With the BAROSTIMâ„¢ NEO System
Kumar, Sanjay
Cardiology
Adult
The purpose of this registry is to provide additional evidence of the safety and benefit of BAROSTIM THERAPY in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the BAROSTIM NEO System
Johnson, Megan A
(715) 389-4878
Ottosen, Rebecca
(715) 393-1471
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Bauer, Anderson
Head/Neck
Adult
Evaluate the structure preservation rate for patients with locally advanced resectable NPNSCC with or without neoadjuvant therapy; all patients will undergo surgical resection and postoperative standard care.
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Clinical Registry Investigating Bardet-Biedl Syndrome
Pomeroy, Jeremy J
Nephrology - Other
Child, Adult
The purpose of the Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) is to establish and perpetuate an international registry enabling subject recruitment for clinical natural history studies, therapeutic trials and collection of biological specimens of blood and saliva specimens of affected individuals and family members with a rare disorder, Bardet-Biedl syndrom (BBS). Biological specimens will be collected for future clinical studies, as well as other studies to examine the relationship between genetic mutations and clinical features. Specimens will be stored in the Core Laboratory.
Marshfield Clinic Research Institute
1000 N OAK AVE
Marshfield, WI  54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449